-
Cancer Management and Research
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Review of catumaxomab in the treatment of malignant ascites
Review
(2336) Views (602) Full article downloads
Authors: Martin Sebastian
Published Date November 2010
Volume 2010:2 Pages 283 - 286
DOI: http://dx.doi.org/10.2147/CMAR.S14115
Martin SebastianDepartment of Internal Medicine III, Hematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
Abstract: Malignant ascites is frequently found with various solid tumors, and no established treatment options exist, apart from symptomatic paracentesis. Catumaxomab, a trifunctional bispecific monoclonal antibody, has two binding specificities directed to epithelial cell adhesion molecule (EpCAM) and the T cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells, including dendritic cells, macrophages, and natural killer cells. The trifunctional approach thus leads to a major histocompatibility complex-unrestricted but specific killing of epithelial tumor cells without need for preactivation or external costimulation. Because EpCAM is expressed in most solid tumors, but not in tissue of mesothelial origin, intraperitoneal treatment with catumaxomab is tumor-specific. Intraperitoneal treatment with catumaxomab resulted in a significant prolongation of puncture-free survival in patients with malignant ascites due to epithelial cancer. Catumaxomab has been approved in Europe for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive epithelial tumors where standard therapy is not available or no longer feasible.
Keywords: catumaxomab, ascites, epithelial cell adhesion molecule
Readers of this article also read:
Optimal management of cancer anorexia–cachexia syndrome
Palliative treatment of malignant ascites: profile of catumaxomab
Cancer chemotherapy: targeting folic acid synthesis
Efficacy and safety of fentanyl buccal for cancer pain management by administration through a soluble film: an update
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
An update on the management of peripheral T-cell lymphoma and emerging treatment options
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Natural killer cells: role in local tumor growth and metastasis
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma




